Peptide for Visceral Fat: UK Treatments Explained

Peptide treatments for visceral fat represent one of the most significant advances in weight management medicine in recent years. Visceral fat, the metabolically active fat stored deep within the abdominal cavity, is strongly linked to type 2 diabetes, cardiovascular disease and other serious conditions. Unlike subcutaneous fat, it cannot be seen or pinched, yet it poses considerable health risks. Licensed peptide medicines, including GLP-1 and dual GIP/GLP-1 receptor agonists, have demonstrated meaningful reductions in visceral adiposity in large clinical trials. This article explains how these treatments work, which are available in the UK, and how to access them safely.

What is visceral fat and why does it matter for your health?

Visceral fat is stored deep in the abdominal cavity and releases inflammatory chemicals into the portal circulation, raising the risk of type 2 diabetes, cardiovascular disease and certain cancers. NHS waist circumference thresholds identify increased and very high cardiometabolic risk.

Visceral fat is the metabolically active fat stored deep within the abdominal cavity, surrounding organs such as the liver, pancreas and intestines, and it carries greater health risks than subcutaneous fat stored just beneath the skin. Unlike the fat you can pinch at the waist, visceral fat releases inflammatory chemicals and free fatty acids directly into the portal circulation, contributing to insulin resistance, raised blood pressure, dyslipidaemia and an increased risk of type 2 diabetes and cardiovascular disease.

NICE guidance on obesity and related conditions recognises that central adiposity, often measured by waist circumference, is a clinically important marker of cardiometabolic risk. The NHS identifies two levels of risk based on waist circumference: increased risk (above 80 cm in women and above 94 cm in men) and very high risk (above 88 cm in women and above 102 cm in men).^[6] These thresholds are lower for people of South Asian, Chinese or Japanese heritage, for whom the NHS advises using lower cut-off values; clinicians should apply ethnicity-adjusted thresholds in line with NHS and NICE guidance.

Visceral fat accumulation is also linked to metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as non-alcoholic fatty liver disease or NAFLD) and to an increased risk of certain cancers, including bowel, breast and oesophageal cancer, as recognised by Cancer Research UK.^[22]

Because visceral fat is not visible and cannot be measured by scales alone, many people are unaware of its extent. MRI and CT scanning provide the most accurate assessment of visceral fat, but they are not used routinely for this purpose outside specific clinical indications or research settings; CT also involves ionising radiation. Waist circumference and waist-to-hip ratio remain practical clinical proxies in everyday care. Addressing visceral fat through lifestyle change, and in some cases pharmacological support, is therefore a meaningful goal in reducing long-term disease burden rather than simply achieving a lower body weight.

How do peptides work to reduce visceral fat?

Licensed peptides reduce visceral fat by activating GLP-1 and GIP receptors to suppress appetite, slow gastric emptying and improve insulin sensitivity, creating a sustained caloric deficit. They do not target fat tissue directly.

Peptides licensed for weight management reduce visceral fat primarily by acting on hormonal pathways that regulate appetite, energy intake and glucose metabolism, rather than by targeting fat tissue directly. The most clinically established of these are glucagon-like peptide-1 (GLP-1) receptor agonists and, more recently, dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonists, which amplify the body's own incretin signalling.

GLP-1 is a gut-derived hormone released after eating. When a GLP-1 receptor agonist such as semaglutide binds to receptors in the hypothalamus, it reduces appetite and promotes satiety. It also slows gastric emptying, which blunts post-meal glucose spikes. The resulting sustained caloric deficit is associated with reductions in visceral and hepatic fat, as reported in imaging substudies within large clinical trials such as the STEP programme for semaglutide and the SURMOUNT programme for tirzepatide. Tirzepatide, which activates both GIP and GLP-1 receptors, has shown additional metabolic effects in clinical studies, including improvements in insulin sensitivity; the precise contribution of GIP signalling to these effects continues to be investigated.

These mechanisms are distinct from older approaches such as stimulant-based appetite suppressants. Because GLP-1 and GIP receptors are expressed in multiple tissues, including the heart, liver and pancreas, the effects observed in trials extend beyond weight loss to include improvements in blood pressure, lipid profiles and markers of hepatic steatosis. For semaglutide 2.4 mg, the SELECT cardiovascular outcome trial demonstrated a reduction in major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease.^[7][8] Reductions in visceral fat are considered by researchers to contribute to these cardiometabolic benefits, though the relative importance of visceral fat loss compared with other mechanisms remains an area of active investigation.

Which peptides are available in the UK for targeting visceral fat?

Three MHRA-authorised peptide medicines are available in the UK: semaglutide (Wegovy), liraglutide (Saxenda) and tirzepatide (Mounjaro), each with specific BMI-based eligibility criteria and dosing schedules.

Three peptide-based medicines are currently authorised by the MHRA for weight management in the UK, each with specific eligibility criteria: semaglutide (Wegovy), liraglutide (Saxenda) and tirzepatide (Mounjaro). All three have demonstrated reductions in visceral and total body fat in clinical trials, though their mechanisms, dosing schedules and licensed indications differ.

Wegovy (semaglutide) is a once-weekly subcutaneous injection licensed for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity. The dose is escalated gradually to a maintenance dose of 2.4 mg weekly, with a higher 7.2 mg strength also authorised by the MHRA. An oral semaglutide formulation for weight management (Wegovy 25 mg tablets) received MHRA authorisation in June 2026 and carries a different licensed posology from Rybelsus, which is authorised only for type 2 diabetes.^[2]

Saxenda (liraglutide) is a once-daily subcutaneous injection with a similar BMI threshold for adults and is also licensed for use in adolescents aged 12 and over who meet specific criteria set out in the SmPC, including BMI at or above the 95th percentile for age and sex.

Mounjaro (tirzepatide) is authorised in the UK both for type 2 diabetes and for chronic weight management. It is administered as a once-weekly subcutaneous injection using a multiple-dose KwikPen, with each pen containing four weekly doses.^[11][12] Clinical trial data from the SURMOUNT programme show tirzepatide produces substantial reductions in visceral adiposity alongside improvements in cardiometabolic markers.^[19]

NICE has issued technology appraisals recommending these medicines within defined criteria. In England, local Integrated Care Boards (ICBs) make commissioning decisions about NHS availability. Devolved nations have separate arrangements: the Scottish Medicines Consortium (SMC) advises NHS Scotland, the All Wales Medicines Strategy Group (AWMSG) advises NHS Wales, and the Health and Social Care Board in Northern Ireland (HSCNI) oversees commissioning there. Specialist weight management services and some GP practices may be able to initiate treatment for eligible patients through these pathways.

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where one of these options may be considered if clinically appropriate.

Are peptide treatments for visceral fat safe and regulated in the UK?

MHRA-authorised GLP-1 and GIP/GLP-1 receptor agonists are rigorously evaluated but carry recognised risks including pancreatitis, gallbladder disease and dehydration, and are contraindicated in pregnancy. Adverse reactions should be reported via the MHRA Yellow Card scheme.

GLP-1 and dual GIP/GLP-1 receptor agonists authorised by the MHRA have undergone rigorous clinical evaluation, but they carry recognised adverse effects and are not appropriate for everyone. The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea and constipation, which are typically most pronounced during dose escalation and tend to improve over time.

Important safety considerations include:

• Pancreatitis: Acute pancreatitis, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, has been reported with GLP-1 receptor agonists.^[1] Patients should be advised to seek prompt medical attention if they develop severe and persistent abdominal pain.

• Gallbladder disease: Rapid weight loss of any cause can increase the risk of gallstones; this has been observed in clinical trials of these medicines.

• Dehydration and kidney effects: Severe or persistent vomiting or diarrhoea can lead to dehydration, which may affect kidney function. Patients should maintain adequate fluid intake and seek medical advice if gastrointestinal symptoms are severe or prolonged.

• Heart rate: A modest increase in resting heart rate has been noted with these medicines; this should be monitored in people with pre-existing cardiac conditions, in line with the relevant SmPC.

• Thyroid: Rodent studies identified C-cell changes at high doses, but the relevance to humans is uncertain.^[17][18] UK SmPCs advise counselling patients on symptoms such as a neck lump, hoarseness or difficulty swallowing.

• Diabetic retinopathy: In people with pre-existing diabetic retinopathy, rapid improvement in blood glucose control may be associated with worsening of retinopathy. People with diabetes and pre-existing retinopathy should discuss retinal monitoring with their clinician before starting treatment.

• Pregnancy and contraception: These medicines should not be used during pregnancy or breastfeeding. Women of childbearing potential should use effective contraception. For tirzepatide specifically, the UK SmPC advises using an additional non-oral contraceptive method for four weeks after starting and for four weeks after each dose increase, as gastrointestinal effects may reduce oral contraceptive absorption.^[11][14]

Suspected adverse reactions to any authorised medicine can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Anyone experiencing symptoms that concern them should contact their GP or, for urgent advice, NHS 111.

How do you access peptide treatment for visceral fat through UK services?

NHS access is governed by NICE appraisals and local commissioning decisions; private access requires a structured prescriber consultation from a GPhC-registered pharmacy. Unlicensed online peptide products should be avoided.

Access to licensed peptide treatments for visceral fat in the UK depends on clinical eligibility, the prescribing route chosen and local commissioning decisions. NHS access is governed by NICE technology appraisals. In England, Integrated Care Boards (ICBs) make local commissioning decisions; in Scotland, NHS Health Boards are advised by the Scottish Medicines Consortium (SMC); in Wales, Local Health Boards are guided by the All Wales Medicines Strategy Group (AWMSG); and in Northern Ireland, the Health and Social Care Board (HSCNI) oversees commissioning. Availability therefore varies across the four nations. Specialist weight management services and some GP practices may be able to initiate treatment for eligible patients.

For those seeking treatment privately, a structured clinical consultation is essential before any prescription is issued. A responsible service should include:

• A full medical history review, including current medications, to identify contraindications and interactions

• BMI assessment, to confirm eligibility against the licensed criteria (which are based on BMI, with or without weight-related comorbidities, as set out in each medicine's SmPC); waist circumference may also be recorded as a clinical risk marker

• Ongoing monitoring, including follow-up appointments to review tolerability, dose escalation and progress

• Clear information about stopping criteria, including when treatment should be paused or discontinued

It is important to be cautious about any service offering peptides for fat loss without a prescriber consultation, or supplying unlicensed or unregulated compounds described as peptides. Some products marketed online as peptides for fat loss are not MHRA-authorised medicines and have no established safety or efficacy data in humans. Purchasing such products carries significant risk.

When choosing a private provider, verify that the pharmacy is registered with the General Pharmaceutical Council (GPhC) at pharmacyregulation.org and that the prescriber is registered with the General Medical Council at gmc-uk.org. In Northern Ireland, pharmacy premises are regulated by the Pharmaceutical Society of Northern Ireland (PSNI). A legitimate online pharmacy will always require a valid prescription from a registered prescriber before dispensing any medicine. Patients should contact their GP if they have concerns about their weight or cardiometabolic health, as NHS pathways remain the most appropriate starting point for many people.

Scientific References

1. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases.
2. First GLP-1 tablet for weight loss approved in the UK.
3. Saxenda (liraglutide) — European Medicines Agency EPAR.
4. Single-dose 7.2mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
5. Medicines regulator approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only.
6. Calculate your waist to height ratio — NHS.
7. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT trial). New England Journal of Medicine.
8. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity (SELECT trial). PubMed.
9. Wegovy (semaglutide) — European Medicines Agency EPAR.
10. MHRA approves GLP-1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults.
11. Mounjaro KwikPen 10mg solution for injection in pre-filled pen — EMC SmPC.
12. Four-dose Mounjaro KwikPen approved by MHRA for diabetes and weight management.
13. Mounjaro KwikPen 2.5mg solution for injection in pre-filled pen — EMC PIL.
14. Mounjaro (tirzepatide) — EMA product information.
15. NICE NG246 Appendix A1: Summary of evidence from surveillance — ethnicity-adjusted BMI/waist thresholds.
16. Women on 'skinny jabs' must use effective contraception, MHRA urges in latest guidance.
17. Knudsen LB et al. Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells. 2010.
18. Suitability of the ICH S1B(R1) weight-of-evidence framework to evaluate GLP-1RA carcinogenicity risk. Regulatory Toxicology and Pharmacology.
19. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine.
20. NICE NG242 Diabetic retinopathy: management and monitoring — Appendix C: effectiveness of intensive glucose-lowering treatments.
21. Angiogenesis and inflammation in the retinopathy risk of insulin and semaglutide — a review. International Journal of Retina and Vitreous.
22. Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review. Drugs.

Frequently Asked Questions